Anti-Kallikrein-15 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the kallikrein loop of human Kallikrein-15, validated for Western blot applications.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog
UniProt
Q9H2R5
Size
100ug
Cat. #
RP2Kallikrein15

In stock

SKU
RP-Kallikrein15

Options

As low as: $130.00

Target Overview

Kallikrein-15 (KLK15, EC 3.4.21.-, UniProt Q9H2R5) is a secreted serine protease belonging to the kallikrein-related peptidase family, a group of 15 trypsin- or chymotrypsin-like enzymes encoded in tandem on chromosome 19q13.4. KLK15 is also known as ACO protease, reflecting its early characterization in certain tissue contexts. The protein is synthesized as a 256-amino acid preproenzyme and processed to an active form following signal peptide cleavage. While KLK15 exhibits proteolytic activity, its physiological substrate specificity remains incompletely characterized. The enzyme is expressed in multiple tissues, including prostate, salivary glands, and certain hormone-responsive tissues, where it is thought to participate in extracellular matrix remodeling and potentially in activation cascades involving other kallikreins or growth factors. Expression profiling and functional studies have implicated KLK15 in cancer progression, particularly in prostate and breast carcinomas, where transcript abundance may correlate with tumor grade or patient outcome. The kallikrein loop region, a structurally conserved feature of the kallikrein family, serves as an immunogenic epitope and is the basis for the immunogen design in Triple Point Biologics' polyclonal antibody reagents.

Background

The kallikrein-related peptidase family has attracted sustained research interest due to its members' roles in proteolytic regulation of hormone signaling, tissue remodeling, and oncogenesis. KLK15 was identified as part of the expansion of the human kallikrein locus and has been studied primarily in the contexts of hormone-dependent cancers and immune tissues. Recent transcript profiling has revealed that KLK15 expression varies significantly across tumor types and may have prognostic value. Lehto et al. (2023) examined kallikrein-related peptidase transcript levels in prostate cancer cohorts and found correlations between KLK family member expression patterns and clinical outcomes, highlighting the potential utility of kallikreins as biomarkers. Similarly, Watrowski et al. (2020) assessed kallikrein gene expression across a panel of breast cancer cell lines, documenting heterogeneous KLK15 mRNA levels that correlated with estrogen receptor status and other molecular features. Beyond oncology, evidence suggests KLK15 may participate in immune modulation. Filippou et al. (2020) reported kallikrein-related peptidase protein expression in lymphoid tissues, proposing that these proteases influence immune cell trafficking or cytokine processing. Transcript diversity is another emerging theme: Adamopoulos et al. (2020) identified six novel alternative transcripts of KLK15 using 3' RACE and high-throughput sequencing, expanding the known isoform repertoire and raising questions about tissue-specific regulation and functional specialization. Together, these findings underscore the complexity of KLK15 biology and the need for validated antibody reagents to distinguish protein expression patterns in experimental models. Triple Point Biologics offers two rabbit polyclonal antibodies raised against the kallikrein loop region of KLK15. Both reagents have been validated in human samples by Western blot and show predicted cross-reactivity with mouse, rat, non-human primate, and canine orthologs based on sequence conservation.

References

  1. Lehto TK et al (2023) Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer. Int J Cancer. PubMed · doi:10.1002/ijc.34551
  2. Watrowski R et al (2020) Gene Expression of Kallikreins in Breast Cancer Cell Lines. Anticancer Res. PubMed · doi:10.21873/anticanres.14219
  3. Adamopoulos PG et al (2020) Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing. Gene. PubMed · doi:10.1016/j.gene.2020.144708
  4. Filippou PS et al (2020) Kallikrein-related peptidases protein expression in lymphoid tissues suggests potential implications in immune response. Clin Biochem. PubMed · doi:10.1016/j.clinbiochem.2019.12.015
  5. Kerr Z et al (2020) Kallikrein-Related Peptidase mRNA Expression in Adenoid Cystic Carcinoma of Salivary Glands: A Polymerase Chain Reaction Study. Head Neck Pathol. PubMed · doi:10.1007/s12105-019-01076-4

Additional Specifications

Gene Symbol KLK15
UniProt ID Q9H2R5
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog
Pack Size 100ug
Immunogen (Kallikrein loop)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 70-100.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 22-256.
Alternate Names KLK15, Kallikrein-15, ACO protease, Kallikrein-related peptidase 15, EC 3.4.21.-

Frequently Asked Questions

What molecular weight should I expect for Kallikrein-15 on a Western blot?

Kallikrein-15 is synthesized as a 256-amino acid preproenzyme with a predicted molecular weight around 28-30 kDa for the mature, processed form after signal peptide cleavage. On reducing SDS-PAGE you will typically observe a band in this range. Depending on your sample source, you may also detect the inactive proenzyme form at a slightly higher molecular weight or glycosylated variants. Post-translational modifications and proteolytic processing can shift the apparent mass, so running a positive control lysate from prostate or salivary gland tissue helps confirm the expected pattern.

Is this Kallikrein-15 antibody predicted to work in mouse and rat samples?

The antibody is validated for human KLK15 and predicted to cross-react with mouse, rat, non-human primate, and dog orthologs based on sequence homology in the immunogen region. However, cross-reactivity is not experimentally validated in these species. If you are working with rodent tissue, we recommend testing at the suggested dilution range and running a human positive control in parallel. Sequence divergence in certain epitope regions may reduce sensitivity or specificity, so empirical titration against your lysate is essential before committing to large-scale experiments.

What starting dilution should I use for Western blot with this KLK15 antibody?

Start at 1:1000 in your standard blocking buffer for Western blot, which is the validated dilution for this polyclonal. KLK15 expression levels vary widely by tissue—prostate and salivary gland are relatively high expressors, whereas many cell lines may express at lower levels. If signal is weak or background is high, bracket between 1:500 and 1:2000 and adjust incubation time or blocking conditions. Always include a no-primary control to assess non-specific binding, especially with polyclonal antibodies where batch variation can influence optimal working concentration.

What tissues or cell lines are good positive controls for Kallikrein-15 expression?

Prostate tissue lysate is the most reliable positive control for KLK15, as the protease is abundantly expressed there and has been extensively studied in that context. Salivary gland tissue also expresses detectable levels. Among cell lines, prostate-derived lines such as LNCaP or PC-3 are reasonable candidates, though expression can be variable and hormone-responsive. If you are working with a novel tissue or cell type, consider running a small RNA panel or checking public expression databases before committing lysate, since KLK15 is not ubiquitously expressed.

Can this antibody distinguish between active and zymogen forms of Kallikrein-15?

This polyclonal antibody recognizes epitopes across a broad region of KLK15 and is not designed to selectively detect the active protease versus the inactive proenzyme. Both forms share the majority of their sequence, differing primarily in N-terminal processing. On a Western blot you may observe multiple bands corresponding to pro-KLK15 and the mature enzyme, but distinguishing them conclusively requires molecular weight reference and functional validation. If activation state is critical to your experiment, consider complementary assays such as activity-based probes or cleavage-specific antibodies where available.

How should I prepare samples to preserve Kallikrein-15 for immunodetection?

KLK15 is a secreted serine protease, so sample handling must account for both its presence in conditioned media and potential autocatalytic or cross-protease activity in lysates. For tissue or cell lysates, work quickly on ice and include a broad-spectrum protease inhibitor cocktail—serine protease inhibitors like AESF or PMSF are particularly important. For conditioned media or biological fluids, clarify by centrifugation and store aliquots at -80°C to minimize freeze-thaw cycles. Avoid boiling samples excessively, as aggregation can obscure bands; 5 minutes at 95°C in reducing buffer is generally sufficient.

What is the recommended storage condition for this Kallikrein-15 antibody?

Store the antibody at -20°C in the original vial or in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titre and increase aggregation over time. Polyclonal antibodies in glycerol-containing buffers are relatively stable, but for long-term storage beyond one year, keep at -80°C. Once thawed for use, an aliquot can be held at 4°C for up to one month if working solution is prepared with sodium azide or another preservative. Always centrifuge briefly before use to pellet any precipitate that may have formed during storage.

Are there known cross-reacting kallikreins I should watch for with this KLK15 antibody?

The kallikrein family comprises 15 closely related serine proteases with substantial sequence homology, particularly in catalytic domains. While this antibody is raised against KLK15-specific regions, some cross-reactivity with other family members—especially KLK3 (PSA), KLK2, or KLK14—cannot be ruled out without explicit testing. If you are working in prostate tissue or other kallikrein-rich contexts, run siRNA or CRISPR knockdown controls for KLK15 to confirm band identity. Public databases and prior literature can help identify which kallikreins are co-expressed in your sample type.

Western blot validation for RP-Kallikrein15 — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Kallikrein-15: Kallikrein loop — WB validation
WB · Panel 1 Kallikrein-15: Kallikrein loop
Kallikrein-15: Catalytic domain — WB validation
WB · Panel 2 Kallikrein-15: Catalytic domain

Custom validation studies available on request — contact us.

Also known as:

  • KLK15
  • Kallikrein-15
  • ACO protease
  • Kallikrein-related peptidase 15
  • EC 3.4.21.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →